At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed residual or relapsed Hodgkin's lymphoma following conventional dose standard chemotherapy
- ✓B symptoms, extranodal disease, or complete remission lasting less than 1 year are allowed
- ✓Must have failed conventional dose standard chemotherapy
- ✕History of myocardial infarction within past 6 months
- ✕Unstable angina
- ✕Uncontrolled infection
- ✕HIV positive
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
High-Dose Chemo-Radiotherapy for Patients With Primary Refractory and Relapsed Hodgkin's Disease
In Brief
A Phase 2 clinical trial evaluating filgrastim, carboplatin, and 9 other interventions for Lymphoma. Completed, enrolled 118 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients with refractory or relapsed Hodgkin's lymphoma.